Non-alcoholic Fatty Liver Disease Clinical Trial
Official title:
A Pilot Project to Assess the Effect of High-intensity Interval Training in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
NCT number | NCT02528305 |
Other study ID # | 2015CM |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | June 2016 |
Verified date | May 2018 |
Source | University of Bath |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot study aims to investigate whether 6 weeks of twice weekly High-intensity Interval Training (HIT) results in improvements in disease-specific measures, feelings of general well-being, physical fitness and cognitive function in patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
Status | Completed |
Enrollment | 12 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 59 Years |
Eligibility |
Inclusion Criteria: - clinical diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis - attending a specialist liver clinic at Ninewells Hospital, Dundee Exclusion Criteria: - unstable cardiovascular disease - uncontrolled arrhythmias - structural cardiac abnormalities - uncontrolled diabetes - other uncontrolled metabolic abnormalities - severe orthopaedic condition that would prohibit exercise - severe pulmonary condition that would prohibit exercise - any other poorly controlled medical condition. - resting systolic blood pressure above 160 mm Hg - resting diastolic blood pressure above 90 mm Hg - symptomatic postural drop in blood pressure greater than 20 mm Hg |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Abertay University | Dundee | |
United Kingdom | Ninewells Hospital | Dundee |
Lead Sponsor | Collaborator |
---|---|
University of Bath | Abertay University |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) | calculation of insulin resistance via formula: fasting insulin (mIU/L) x fasting glucose (mg/dL)/405 normal insulin resistance -HOMA score <3 moderate insulin resistance -HOMA score 3-5 severe insulin resistance -HOMA score >5 Assessed at baseline, after 6 week control period and within 1 week of completing 6 weeks HIT | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Oral Glucose Tolerance Test | measurement of capillary samples for glucose at time 0, followed by every 20 minutes for 2 hours following ingestion of 75g glucose. Results graphed against time, then area under the curve calculated for each of the 3 assessments. | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | AST: ALT Ratio | ratio of liver enzymes aspartate aminotransferase (AST) to alanine aminotransferase (ALT). used as a diagnostic aid e.g. AST:ALT of more than 2:1 is characteristic of alcoholic liver disease whereas fatty steatosis and many other causes of liver disease, ratio is less than or equal to 1. Ratio may rise as fibrosis and cirrhosis develop in viral hepatitis. |
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | FIB-4 | calculated from AST, ALT, platelets and participant's age and used to estimate amount of fibrosis in liver. Fib-4 score of <1.45 has negative predictive value of 90% for advanced fibrosis. |
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Body Fat Mass Estimated Via Bioimpedance | total body fat and trunk fat estimated via bioimpedance measured after overnight fast, expressed as percentage | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Blood Pressure | taken with participant supine, measured on left arm | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | General Well-being as Assessed by SF-36 Questionnaire | Assessment of: physical functioning, social functioning, mental health, pain, change in health, physical role limitation, mental role limitation, energy and vitality, health perception over preceding 4 weeks (other than change in health, which is a comparison to health the preceding year), expressed as a transformed score range 0-100, with a higher score indicating better function/freedom from pain etc | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Short-term Memory Recall | testing of verbal word presentation-immediate recall of 10 words (60 seconds for recall) Maximum =10, minimum =0 | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Estimated VO2 Max | VO2 max estimated via submaximal exercise test-submaximal treadmill walking test Calculated via formula: VO2max= 15.1+21.8 x speed (miles per hour) - 0.327 x heart rate (beats per minute) - 0.263 x speed x age (years) + 0.00504 x heart rate x age + 5.98 x gender (0=female, 1=male) | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Physical Function-"Get up and go" Test | participant will be timed standing up from chair unaided,walking 30m, turning round and returning to a seated position on the chair, the average time of 3 attempts will be recorded. | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Ankle Brachial Pressure Index (ABPI) | ratio of blood pressure in left arm and right ankle | Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Long-term Memory Recall | testing of verbal word presentation-delayed recall of 10 words 10 minutes after words initially presented (within 60 seconds). Maximum= 10 words, minimum = no words |
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks | |
Primary | Executive Function (Verbal Fluency Test) | written verbal fluency test: participant asked to write down as many English words as possible within 60 seconds, starting with a particular letter of the alphabet, excluding proper nouns or plurals. Baseline assessment-letter A Post Control assessment -letter S After HIT assessment -letter F |
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |